On The Pen GLP-1 News

Medical

On The Pen is the leading GLP-1 news podcast and platform covering obesity medicine, FDA actions, drug shortages, access policy, and the business of NuSH therapies. The podcast is in the top 1% of all podcasts globally, and On The Pen is a top...

Episodes

We’re Solving Obesity. Now Who Pays for It?

GLP-1 Coverage Is COLLAPSING in 2027

$50 Zepbound Incoming? China Has US in a GLP-1 “Chokehold”

200 GLP-1 Deaths, Chrissy Metz & a Stunning Harvard Study

Eli Lilly Earnings Call Recap: Retatrutide News

Novo Nordisk Warned us For Years About Synthesized Semaglutide. Now They Want In.

Retatrutide Biologic Battle: The Story Gets Bigger

GLP-1 Showdown: Inside The High Stakes War over Patients

Medicare, New Drugs, and a Surprising GLP-1 Trend, What Patients Need to Know

Compound GLP-1 Poll STUNS THE INTERNET!

How To Get $50 GLP-1

What Comes After Zepbound? The Biggest ADA 2026 Obesity Drug Breakthroughs

Retatrutide Just Reached Bariatric Surgery Results

Retatrutide Before FDA Approval? Lilly Just Changed the Conversation

Eli Lilly Isn’t Telling Us About Their Future Obesity Drugs

Retatrutide, Multi Agonist Obesity Drugs, and the PBM Access War

Lilly Bets $8B on Weight Loss Future

The Next Two Weeks in GLP1 Are Huge, Here's Why

He Took Retatrutide 40mg and Proved a Point

Eli Lilly Just Revealed Something About The GLP-1 Market